The firm has started referring to itself as a CDMO, which stands for contract development and manufacturing organisation, in a bid to position itself in the market as a company that is bringing together drug development and manufacturing expertise within a single organisation. "CDMO describes organisations that have reached a point where they can work with customers from very early pre-formulation work all the way through scale-up and commercialisation," John Feik, director of marketing and corporate development at DPT told Outsourcing-Pharma at the recently-held Interphex trade show in Philadelphia. "We've begun to communicate that we're a CDMO because we didn't want to be classified as just a contract manufacturing organisation (CMO) that provided only manufacturing services. Additionally, if we labelled ourselves as a contract research organisation (CRO), that wouldn't recognise our manufacturing capabilities. CDMO seemed to encompass both service offerings," said Feik. "We believe that we and others in our industry have reached a high level of integration with these functions and more traditional terms such as CRO and CMO have become obsolete". According to Feik, when a contract services provider has that fully integrated continuum of capabilities, it simplifies matters significantly for the customer. "The customer is no longer is forced to work with multiple, non-integrated providers throughout the process. This approach saves customers both time and money," he said. As yet, Feik said that there are only a handful of service providers that can fully integrate the drug development process from early-stage to full-scale manufacturing. As such, he said that CDMO is not yet a widely used or even recognised term within the pharma industry, but there are a few organisations starting to use the term, and DPT believes this term best describes companies that offer this range of services. "There are several demanding disciplines along the development pathway and relatively few organisations can provide these capabilities at an extremely high level of expertise," he said. "We've offered a full range of development and manufacturing services for many years. More recently, we have begun to hear that our customers appreciate how well these services work together." While these new generation of CDMOs begin to evolve and gain momentum within the industry, Feik believes that there will likely always be a demand for some pure CMOs and CROs, particulary if they are serving a niche market. "However, we see more and more customers looking for the combination of a one-stop solution to their development and manufacturing needs and specific dosage form expertise," he said. "It is clear that the integrated approach to services is where the market is trending."